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ABSTRACT  
Although excessive consumption of ethanol in alcoholic beverages causes multi-
organ damage, moderate consumption, particularly of red wine, is protective against 
all-cause mortality. These protective effects could be due to one or many 
components of the complex mixture of bioactive compounds present in red wine 
including flavonols, monomeric and polymeric flavan-3-ols, highly coloured 
anthocyanins as well as phenolic acids and the stilbene polyphenol, resveratrol. The 
therapeutic potential of resveratrol, firstly in cancer chemoprevention and then later 
for cardioprotection, has stimulated many studies on the possible mechanisms of 
action. Further indications for resveratrol have been developed, including the 
prevention of age-related disorders such as neurodegenerative diseases, 
inflammation, diabetes and cardiovascular disease. These improvements are 
remarkably similar yet there is an important dichotomy: low doses improve cell 
survival as in cardio- and neuro-protection yet high doses increase cell death as in 
cancer treatment. Fewer studies have examined the responses to other components 
of red wine, but the results have, in general, been similar to resveratrol. If the non-
alcoholic constituents of red wine are to become therapeutic agents, their ability to 
get to the sites of action needs to be understood. This mini-review summarizes 
recent studies on the possible mechanisms of action, potential therapeutic uses and 
bioavailability of the non-alcoholic constituents of alcoholic beverages, in particular 
resveratrol and other polyphenols.  
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INTRODUCTION 
Alcohol-related disorders account for an enormous part of the global mortality and 
morbidity (Rehm et al., 2003). Chronic alcohol abuse may lead to organ damage and 
carcinoma, especially to the liver and pancreas, but also damage to the brain 
(Harper, 2007) and immune system (Cook, 1998) as two of many examples. On the 
other hand, epidemiological studies indicate that light to moderate consumption of 
alcoholic beverages reduces all-cause mortality (De Lorimier, 2000). In particular, red 
wine consumption is inversely associated with mortality due to cardiovascular 
diseases (Gronbaek, 2002), and the protective effects are observed for consumption 
levels up to 300 ml wine per day (Rotondo et al., 2001). The reductions in risk from 
low to moderate consumption of alcoholic beverages are greater for red wine 
compared to white wine, beer and most spirits (Gronbaek, 2002). The potential 
association between red wine consumption and risk of cardiovascular disease 
mortality has been highlighted by the „French Paradox‟ which refers to the finding that 
people in France suffer from a relatively low incidence of coronary heart disease, 
despite their diet being rich in saturated fats (Renaud & de Lorgeril, 1992). This 
concept has been intensely dissected with Ferrières (2004) concluding “that the 
promotion of primary prevention, based on an optimal diet rich in fruit and vegetables, 
regular physical exercise, and life without smoking, is worthwhile.” 
 
This phenomenon was first noted by the Irish physician Samuel Black (1819) who 
attributed the observation to the French habit of drinking red wine with meals, while 
the first scientific study was published by Cabot (1904), and the first comparison of 
coronary heart disease mortality between wine-drinking countries and those where 
beer or spirits were consumed was made 75 years later (St. Leger et al., 1979). The 
effect has since been ascribed to a number of red wine components including 
ethanol, which at low doses has beneficial effects on cardiovascular disease risk, and 
various polyphenols derived from the grape skins, seeds and stems or during 
maturation in oak barrels (Booyse et al., 2007).  
 
Red wine contains a complex mixture of bioactive compounds that are predominantly 
phenolic in nature (Soleas et al, 1997). These include flavonols such as myricetin, 
kaempferol and the predominant quercetin, the flavan-3-ol monomers catechin and 
epicatechin, the oligomeric and polymeric flavan-3-ols or proanthocyanidins, various 
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highly coloured anthocyanins, various phenolic acids (gallic acid, caftaric acid, caffeic 
acid, p-coumaric acid) and the stilbene resveratrol (figure 1). These compounds 
occur in red wine but are virtually absent from white wine because the skins, seeds 
and stems are present during the fermentation of red wine but not white wine. Red 
wine is one of the richest sources of polyphenols in human diets. Highly tannic red 
wines can contain up to 3 g of total polyphenols per litre, and moderate red wine 
drinkers will consume polyphenols at levels well above the population average 
(Waterhouse, 2002). Urinary resveratrol measurements have been proposed as a 
robust marker of wine intake (Zamora-Ros et al, 2009). Resveratrol is synthesized in 
the skins of grapes as a response to fungal infection. Once present, the compound 
acts as a phytoalexin, preventing the proliferation of pathogens. Rich natural sources 
of resveratrol include Polygonum cuspidatum (Japanese knot-weed, 0.524 mg/g), red 
wines (0.1 – 14.3 mg/l), red grape skins, berries such as blueberries, as well as 
peanuts and other nuts (Baur & Sinclair, 2006).  
 
There is a substantial literature on the biological activities of phenolic compounds that 
are present in red wine. Much of the early interest centred on quercetin, a potent anti-
oxidant that is present as a mixture of glycosides and the aglycone in red wine (Burns 
et al., 2000). Quercetin has been shown, in vitro and in animal models, to possess a 
range of biological activities relevant to protecting against cardiovascular diseases 
(Perez-Vizcaino et al., 2006) and against cancer (Birt et al., 2001; Moon et al., 
2006a).  
 
There has been considerable interest in resveratrol and other polyphenols in red 
wine in relation to human health. This mini-review summarizes the current knowledge 
about the various beneficial effects of resveratrol and other polyphenols from wine in 
the prevention of ageing-related disorders such as cancer, neurodegenerative 
disorders, inflammation and cardiovascular disease; further, the possibility that 
resveratrol may be useful in the treatment of these diseases will be mentioned. A 
critical issue for resveratrol and other polyphenols as potential therapeutic agents is 
whether adequate concentrations can be achieved at the sites of action; thus, the 
bioavailability and efficacy of these compounds in humans are outlined at the end of 
this article. 
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Resveratrol: the evidence for potential benefits to human health  
There is substantial evidence that resveratrol prevents or delays the onset of chronic 
diseases such as diabetes, inflammation, Alzheimer‟s disease and cardiovascular 
disease that increase in prevalence with age as well as inducing neuroprotection and 
inhibiting proliferation of human cancer cell lines (Aggarwal et al, 2004; Baur & 
Sinclair, 2006; Das & Maulik, 2006; Das & Das, 2007b; Opie & Lecour, 2007; 
Vidavalur et al, 2006; Harikumar & Aggarwal, 2008; Raval et al, 2008; Saiko et al, 
2008). The breadth of the therapeutic potential of resveratrol is shown by the 
extension of the lifespan and improved motor function in mice fed a high-calorie diet 
(Baur et al, 2006). This impressive study indicates new approaches for treating 
obesity-related diseases and the diseases of ageing. The prevention or treatment of 
cardiovascular disease has been a major research theme in resveratrol studies. The 
potential benefits cover the range of cardiovascular problems, including myocardial 
infarction, arrhythmias, hypertension, hypertrophy, inflammation leading to fibrosis, 
atherosclerosis and thrombosis.  
 
Resveratrol extends the lifespan of species such as yeast, worms and flies by 
activation of the silent information regulator 2 (SIR2), one of the sirtuins (Baur & 
Sinclair, 2006). The sirtuins as class III histone deacetylases regulate key pathways 
by removing acetyl groups from the -amino group of lysine to silence transcription. 
Multiple metabolic pathways are regulated by SIRT1, the mammalian analogue of 
SIR2, as this enzyme is involved in lifespan regulation, the cellular response to 
stress, glucose homeostasis, insulin secretion and lipid mobilization (Jiang, 2008). 
SIRT1 is a key regulator of vascular endothelial homeostasis controlling 
angiogenesis, vascular tone and endothelial dysfunction (Potente & Dimmler, 2008). 
The cardiac responses to low (2.5 fold) or moderate (7.5 fold) overexpression of 
SIRT1 in transgenic mouse hearts included attenuation of age-dependent increases 
in heart weight, apoptosis, fibrosis and cardiac dysfunction while high (12.5 fold) 
overexpression increased apoptosis, heart weight and decreased cardiac function 
(Alcendor et al, 2007).  
 
While the pharmacological actions of resveratrol have been linked to antioxidant 
actions, the possible link between sirtuin activation and redox regulation by 
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resveratrol is not yet clear. Hypoxia-induced apoptosis in embryonic rat heart-derived 
H9c2 cells was greatly decreased following treatment with resveratrol by activation of 
SIRT1 increasing the ability of FOXO1 (Forkhead box factors regulated by 
insulin/Akt) to induce cell cycle arrest (Chen et al, 2009). The ability of the FOXO 
transcription factor FOXO3 to induce cell cycle arrest and resistance to oxidative 
stress was increased by SIRT1 (Brunet et al, 2004). Moderate expression of SIRT1 
protected the heart from oxidative stress and increased expression of antioxidant 
enzymes but high expression increased oxidative stress (Alcendor et al, 2007). 
Cilostazol, a selective inhibitor of phosphodiesterase III, dose-dependently increased 
SIRT1 expression to protect human endothelial cells after ischemic vascular damage 
through increased production of nitric oxide (Ota et al, 2008). These studies suggest 
that sirtuins are important in the resistance to oxidative stress induced by resveratrol, 
but the details need to be determined.  
 
The breadth of the therapeutic potential for resveratrol hides a contradiction: how can 
the same compound improve the survival of cells as a cardioprotective or 
neuroprotective agent, yet kill cancer cells? Although the limited literature makes 
comparison of doses difficult, the general trend is that higher doses are needed to kill 
cancer cells than to improve cell survival. Possible reasons include dose-dependent 
effects, either at the level of the molecular mechanisms as described above for 
SIRT1, or by activation of different pathways at different resveratrol doses. In the 
heart, resveratrol at lower doses (5 mg/kg) activated survival signals by up-regulating 
the antiapoptotic and redox proteins Akt and Bcl-2 while higher doses of 25 mg/kg 
potentiated a death signal by down-regulating redox proteins and up-regulating pro-
apoptotic proteins (Dudley et al, 2008). Although resveratrol is usually considered as 
an antioxidant, primarily by increasing NO bioavailability, resveratrol can also exhibit 
pro-oxidant properties in the presence of transition metal ions such as copper, 
leading to oxidative breakage of cellular DNA (Alarcón de la Lastra & Villegas, 2007). 
These authors suggest that this pro-oxidant action is the common mechanism for 
anticancer and chemopreventive properties of plant polyphenols.  
 
Resveratrol and chemoprevention 
The initial reports of anti-cancer responses to resveratrol led to the increased interest 
in this compound from 1992 (Baur & Sinclair, 2006). Resveratrol inhibited or retarded 
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the growth of a wide range of human cancer cells in culture as well as implanted 
tumours usually in mice (Aggarwal et al, 2004; Athar et al, 2007). The compound 
inhibited experimental tumourigenesis in a wide range of animal models by targeting 
many components of intracellular signaling pathways including pro-inflammatory 
mediators, regulators of cell survival and apoptosis, and tumour angiogenic and 
metastatic switches by modulating a distinct set of upstream kinases, transcription 
factors and their regulators (Kundu & Surh, 2008; Pirola & Fröjdö, 2008). However, 
the role of sirtuin activation by resveratrol has not been defined. Khan et al (2008) 
have presented the key findings from studies on the effects of dietary antioxidants 
including tea polyphenols, curcumin, genistein, resveratrol, lycopene, pomegranate 
and lupeol against cell lines from human skin, prostate, breast, lung and liver 
cancers. Many of the same compounds, including resveratrol, curcumin and 
epigallocatechin gallate, modulated the effects of deregulated cell cycle checkpoints, 
and this could contribute to the prevention of cancer (Meeran & Katiyar, 2008). 
However, it should be emphasised that these results are measurements of 
resveratrol responses on human cancer cells in culture, or taken as conclusions from 
epidemiological studies, rather than the results from clinical trials with cancer 
patients. No clinical trials with resveratrol in human cancers have been reported 
although 5 trials on human cancers are underway or finished 
(http://www.clinicaltrials.gov/ct2/results?term=resveratrol).   
 
Resveratrol and inflammation 
Inflammation is a pervasive cause of disease, implicated in diseases as diverse as 
metabolic syndrome (Dandona et al, 2005), rheumatoid arthritis and 
neurodegenerative disorders (Stolp & Dziegielewska, 2008). The cardioprotective 
and cancer preventive actions of resveratrol may be attributable to anti-inflammatory 
effects such as the inhibition of synthesis and release of pro-inflammatory mediators, 
modifications of eicosanoid synthesis, inhibition of some activated immune cells, or 
inhibiting enzymes such as cyclooxygenase-1 (COX-1) or cyclooxygenase-2 (COX-2) 
through to the inhibitory effect of resveratrol on transcription factors such as nuclear 
factor kappaB (NFkappaB) or activator protein-1 (AP-1) (Das & Das, 2007a; 
Udenigwe et al, 2008). Numerous studies have confirmed that resveratrol suppresses 
TNF- 
have shown significant suppression of IL-1, IL-6 and IL-8 with resveratrol (Aggarwal 
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et. al., 2004, Marier et. al., 2005, Donnelly et al. 2004). In an acute in vivo study, 
resveratrol inhibited the generation of adhesion molecules (Das et al., 2006b).  
 
Resveratrol and diabetes 
In rat models of diabetes, resveratrol reduced blood glucose and triglyceride 
concentrations following streptozotocin treatment (Su et al, 2006) and prevented the 
increase in blood pressure and cardiac hypertrophy while restoring the mesenteric 
and cardiac eNOS activity and decreasing oxidative stress in fructose-fed rats 
(Miatello et al, 2005). In obese Zucker rats, a genetic model of type-2 diabetes, 
resveratrol increased GLUT-4 expression and reduced endothelin expression and 
cardiac apoptosis in ischaemic-reperfused hearts (Lekli et al, 2008). Resveratrol 
increased insulin sensitivity by lowering the blood glucose level in high calorie diet 
mice with reduced insulin-like growth factor-1 (IGF-I) and increased AMP-activated 
protein kinase (AMPK) playing a major role (Baur et al, 2006). Resveratrol attenuated 
diabetic nephropathy in rats (Sharma et. al., 2006a), reduced thermal hyperalgesia 
and cold allodynia in streptozotocin-induced diabetic rats (Sharma et. al., 2006b) and 
attenuated diabetic neuropathic pain through changes in NO and TNF- (Sharma et. 
al., 2007).  
 
Resveratrol and gastrointestinal diseases 
Helicobacter pylori causes peptic ulcer and gastrointestinal cancers. Cancer 
prevention requires control of the infection and the subsequent inflammatory 
processes. Plant products including resveratrol inhibited H. pylori colonization, 
decreased gastric inflammation by inhibiting cytokine and chemokine release, and 
repressed precancerous changes by inhibiting nuclear factor-kappa B DNA binding, 
inducing profuse levels of apoptosis and inhibiting mutagenesis (Lee et al, 2008). 
 
Resveratrol and neuroprotection 
The first evidence that resveratrol crosses the blood-brain barrier was published by 
Virgili & Contestabile (2000). In this study in young adult rats, chronic administration 
of resveratrol protected against the damage caused by the systemic injection of the 
excitotoxin kainic acid in the olfactory cortex and the hippocampus. Resveratrol 
effectively protected the brain from traumatic brain injury (Ates et al., 2006) and also 
inhibited the excitatory synaptic transmission in rat hippocampus (Gao et al., 2006). 
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Resveratrol preconditioning and protection of brain cells in vitro from ischemic injury 
was mediated by SIRT1 (Raval et al, 2006). A similar study showed the 
neuroprotective effect of resveratrol by inhibiting the voltage-activated potassium 
currents in hippocampal neurons (Gao and Hu, 2005). In a study of spinal cord 
ischemia model, resveratrol-induced neuroprotection was mediated by decreased 
oxidative stress and increased NO release (Kiziltepe et al., 2004). Zamin et al. (2006) 
suggested that PI3-kinase/Akt pathway but not mitogen-activated protein kinase 
(MAPK) is involved in the neuroprotection.  
 
Resveratrol and myocardial injury 
Preconditioning describes the development of resistance to damage caused by 
prolonged ischemia and reperfusion to the heart (Bolli, 2007). Coordinated up-
regulation of iNOS–VEGF–KDR–eNOS by resveratrol has been suggested by Das et 
al (2005a) as the preconditioning mechanism in rat hearts. Resveratrol likely 
activates both adenosine A1 and A3 receptors which phosphorylate PI-3 kinase, 
which then phosphorylates protein kinase B (Akt) and thus preconditions the heart by 
producing NO as well as by the activation of antioxidant Bcl-2 (Das et al, 2005a, 
2005b). Activation of adenosine A3 receptors could also precondition the heart by a 
survival signal through the cAMP response element-binding protein (CREB) 
phosphorylation via PI-3 Kinase–Akt and via MEK (Mitogen-activated extracellular 
signal-regulated protein kinase)–CREB pathways (Das et al., 2005c). Recent studies 
have also demonstrated that NO can induce the expression of heme oxygenase-1. 
Das et al. (2006a) showed that tin protoporphyrin (SnPP), a heme oxygenase-1 
inhibitor, abolished the increased cardiac function parameters, reduced myocardial 
infarct size and decreased cardiomyocyte apoptosis that characterise the 
cardioprotection with resveratrol. The heme oxygenase-1 mediated mechanisms 
were related to the p38MAP kinase and Akt survival signaling, but independent of 
NFB activation. Being a polyphenol, resveratrol protects the heart by its anti-
oxidative properties through various redox signalling mechanisms. The ability of 
resveratrol to modulate redox signalling has been extensively reviewed (Das & 
Maulik, 2006; Vidavalur et al, 2006) but the role of sirtuin activation in the heart is yet 
to be determined. White wine lacking polyphenols but containing antioxidant 
compounds such as caffeic acid and tyrosol mediated cardioprotection against 
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ischemia-reperfusion injury in rat hearts by a similar survival pathway involving 
Akt/FOXO3a/NFB (Thirunavukkarasu et al, 2008).  
 
Resveratrol and hypertension 
The concept that reactive oxygen species contribute to the cause and the 
development of complications of hypertension is well supported by many clinical and 
experimental studies (Li & Shah, 2004). However, systolic blood pressure was not 
lowered by resveratrol in young stroke-prone spontaneously hypertensive rats 
(SHRSP) although oxidative damage to DNA and glyoxidative damage in vivo were 
decreased (Mizutani et al, 2001). Consistent with these findings, administration of 
quercetin in the diet of young SHR did not delay or lessen the onset or severity of 
cardiovascular complications, including hypertension (Carlstrom et al, 2007). In 
contrast, rats with abdominal aortic constriction showed anti-hypertensive and anti-
hypertrophic responses to quercetin administered in the food, but without changes in 
vascular and myocardial function (Jalili et al, 2006).  
 
Resveratrol and angiogenesis 
The formation of new blood vessels is a potential mechanism to reduce ischemic 
damage to the heart. Ischemia induces VEGF release to encourage the development 
of collateral coronary circulation. Reactive oxygen species may have an important 
role in activating this process of myocardial angiogenesis (Maulik, 2006). Resveratrol 
enhanced angiogenesis both in vivo and in vitro by induction of VEGF which was 
regulated by thioredoxin-1 and heme oxygenase-1 (Kaga et al, 2005). This could be 
an important mechanism mediating cardioprotection in the chronic ischemic 
myocardium. 
 
Resveratrol and the endothelium 
Endothelial dysfunction is a characteristic finding in coronary heart disease. 
Resveratrol appears to protect endothelial cells at multiple targets. In a rat model of 
injured aorta, a lower dose of resveratrol (10 mg/kg) increased the proliferative, 
migrative and adhesive activities of endothelial progenitor cells, enhanced eNOS 
expression and accelerated the repair of the injured artery; however, a higher dose 
(50 mg/kg) had minimal effects (Gu et al, 2006). Chemokines in endothelial cells 
such as fractalkine are critical in the initiation, maintenance and resolution of 
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inflammation. Resveratrol inhibited monocyte adhesion to human endothelial cells 
induced by TNF- 
in organs such as the heart (Moon et al, 2006b). The expression of the atherogenic 
cytokine, monocyte chemoattractant protein-1, was suppressed by about 45% at a 
resveratrol concentration of 50 mol/l; this suppression was not altered by heme 
oxygenase-1 inhibition or knockdown indicating a distinct signalling pathway (Cullen 
et al, 2007). At submicromolar resveratrol concentrations, TNF--induced NFB 
activation, inflammatory gene expression and monocyte adhesiveness to human 
coronary arterial endothelial cells were inhibited; these anti-inflammatory actions on 
endothelial cells could lead to cardioprotection (Csiszar et al, 2006).  
 
As the cells lining blood vessels, endothelial cells are sensitive to increased levels of 
reactive oxygen species in the blood, or produced in the vasculature by NADPH 
oxidase. The stimulation of this enzyme by oxidised LDL in vascular endothelial cells 
was inhibited by resveratrol by reducing the membrane association of two of the 
proteins in the active enzyme complex, gp91 (phox) and Rac1 (Chow et al, 2007). 
Resveratrol pre-treatment prevented the increase in caspase 3/7 activity produced by 
oxidised LDL and TNF- 
of the antioxidant systems, glutathione peroxidase and heme oxygenase-1 (Ungvari 
et al, 2007). The oxidant species, peroxynitrite, induced apoptotic changes in aortic 
endothelial cells in culture; resveratrol concentrations from 1-25 mol/l caused a 
concentration-dependent decrease in these apoptotic changes (Brito et al, 2006). 
Leukocyte activation, transmigration and target cell adhesion following ischemia-
reperfusion are important in the development of graft rejection following 
transplantation. Following tissue allotransplantation, rats treated with resveratrol 
showed a moderate survival prolongation and reduction of lymphocytic infiltration and 
necrosis (Hsieh et al, 2007).  
 
Flavanoids such as quercetin and wine polyphenols prevented endothelial 
dysfunction and reduced blood pressure, oxidative stress and end-organ damage in 
hypertensive animals, while flavanoid-rich foods improved endothelial function in 
cardiovascular patients (Perez-Vizcaino et al, 2006). An acute improvement in flow-
mediated vasodilatation was measured after administration of a red grape extract 
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containing epicatechin, catechin, resveratrol, rutin and other polyphenols to patients 
with coronary heart disease (Lekakis et al, 2005). 
 
Resveratrol and collagen deposition 
Resveratrol inhibited cardiac fibroblast proliferation and differentiation to the 
hypersecretory myofibroblast phenotype in rat cardiac fibroblasts in culture; these are 
two critical steps in cardiac collagen deposition (Olson et al, 2005). Fibrosis is the 
final result of an inflammatory challenge and thus inflammation plays a key role in 
organ damage in chronic cardiovascular disease. Resveratrol interacts at multiple 
sites within the inflammatory pathways to decrease inflammation (Das & Das, 
2007a).   
 
Multiple actions of dietary polyphenols have been proposed for reducing 
inflammation as well as in the processing of lipids in the body to improve the blood 
lipid profile to eventually reduce the risk of coronary heart disease (Zern & 
Fernandez, 2005). The processes of initiation, progression and rupture of 
atherosclerotic plaques offer many targets to delay or prevent cardiovascular 
disease. There is much experimental evidence that the phenolic compounds in wine 
alter these processes as part of their cardioprotective actions (Szmitko & Verma, 
2005).  
 
Resveratrol and blood coagulation 
Tissue factor (TF) is the primary initiator of the blood coagulation cascade. Thrombus 
formation at the site of complicated atherosclerotic lesions following exposure to TF 
is a major cause of death in industrialized countries. In human umbilical vein 
endothelial cells and mononuclear cells, resveratrol and quercetin reduced the 
expression of TF mRNA by bacterial lipopolysaccharide, interleukin-1 - 
-10-fold more effective 
in inhibiting TF production in human peripheral blood mononuclear cells than the 
parent compound (Kaur et al, 2007).  
 
The prevention of excessive or inappropriate aggregation of platelets decreases 
thrombus formation, reduces the subsequent blockage of small blood vessels and 
thereby reduces the risk of stroke and myocardial infarction. Many studies, reviewed 
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by Baur & Sinclair (2006), have shown that resveratrol prevents platelet aggregation 
in vitro, probably by selective inactivation of cyclooxygenase-1.  
 
One of the potential mechanisms to explain this wide range of cardioprotective and 
vascular protective actions is the removal of highly reactive free radicals such as 
superoxide following increased expression of heme oxygenase-1 (Huang et al, 2005; 
Juan et al, 2005). Low concentrations of resveratrol (1-10 mol/l) likely to be 
physiologically relevant increased heme oxygenase-1 expression, at least partly 
through actions on the NFB pathway in human aortic smooth muscle cells in culture 
(Huang et al, 2005; Juan et al, 2005). However, the increased expression of heme 
oxygenase-1 has been attributed to regulation by MAP kinase and Akt survival 
signalling in the rat heart, not by activation of the NFB pathway (Das et al, 2006a). 
 
Bioavailability and bioefficacy of resveratrol and other polyphenols in humans 
At high doses, orders of magnitude higher than would be achievable through red 
wine consumption by humans, orally ingested resveratrol is also able to extend 
lifespan in a number of organisms ranging from mono-cellular yeasts to animals such 
as mice. These findings are remarkable, with lifespan extension of greater than 50% 
reported for certain species of yeast, nematode, insect and fish (Howitz et al., 2003; 
Wood et al., 2004; Valenzano et al., 2006). It has also been demonstrated that high 
doses of resveratrol can prevent the detrimental effects of a high fat diet in a mouse 
model of obesity (Baur et al., 2006), another truly remarkable observation with wide-
ranging implications for mankind considering the obesity epidemic that is sweeping 
the western world. But, it must be recognised that all these observations have been 
made with doses of resveratrol that are well above those achievable in humans 
though normal diet. Red wine is almost the only source of resveratrol in human diets, 
and the richest red wines contain about 7 mg resveratrol per litre. To achieve the 
equivalent dose of resveratrol that was fed to the fish in order to achieve a >50% 
lifespan extension (Valenzano et al., 2006) and to mice in order to prevent the 
detrimental effects of a high fat diet (Baur et al., 2006), one would need to consume 
around 60 litres per day of high resveratrol red wine, which is clearly not feasible. 
Therefore, these potential effects of resveratrol remain achievable through 
pharmaceutical means only and not through dietary means. It is interesting to note 
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that other dietary components have been shown to be effective in extending lifespan, 
including blueberry polyphenols (Wilson et al., 2006). 
 
Flavan-3-ols, or the catechins and their oligo- and poly-meric derivatives the 
proanthocyanidins, have also attracted considerable interest due to their ability to 
improve endothelial function, vascular tone and platelet reactivity in vivo. In particular, 
ingestion of cocoa flavan-3-ols has been shown, consistently, to improve vascular 
function (Schroeter et al., 2006; Heiss et al., 2007) and platelet reactivity (Rein et al., 
2000). These observations have been consistent across a number of studies and the 
required dose of epicatechin has been estimated at 1-2 mg per kg body weight 
(Schroeter et al., 2006). The concentration of (-)-epicatechin in red wine is in the 
range of 20-200 µM but (+)-catechin is present at 200-500 µM (Burns et al., 2000).  
 
Absorption from the gut 
The ability of a dietary component to influence vascular function and prevent 
cardiovascular disease is dependent on how much of the oral dose is absorbed from 
the gut, the influence of metabolism during the first pass (small intestine and liver) 
and the subsequent exposure that is a function of the excretion rate which is 
reflected in the plasma half life. It is possible that some wine compounds may 
accumulate in certain tissues and hence increase the exposure at these specific 
sites. Although there is some evidence that certain polyphenols accumulate to higher 
concentrations in certain body tissues compared to others, there is considerably 
more evidence (from animal experiments) showing that dietary polyphenols do not 
become concentrated in specific tissues, besides those of the gut. Nevertheless, 
there is some evidence that resveratrol accumulates in a time- and dose-dependent 
manner in the liver (Vitaglione et al., 2008) and brains (El-Mohsen et al., 2006) of rats 
intragastrically administered resveratrol over a period of days, while another report 
indicates preferential fixation of 14C-resveratrol in the organs of absorption and 
elimination (stomach, intestine, liver, kidney) (Vitrac et al., 2003). 
 
Polyphenols are only partially absorbed and only a fraction is excreted via the urine in 
humans. The plasma concentrations achieved and the urinary yield as a function of 
oral dose depends on a number of factors, but by far the most important is the 
structure of the polyphenol. Almost without exception, phenolics in plants are 
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glycosylated, and this is true of most plant-derived foods and beverages also. 
Glycosylation can have an enormous influence on the efficiency of absorption and 
the site of absorption – monoglucoside derivatives are preferentially absorbed from 
the small intestine and are better absorbed than other glycosides such as 
rhamnoglucosides, that are absorbed later (probably from the colon) and to a lesser 
extent. The enhanced absorption of monoglucosides from the small intestine is due 
to human small intestinal lactase enzyme that has the capacity to hydrolyse flavonoid 
glucosides and which is required for absorption and metabolism of these compounds 
(Németh et al., 2003). Some polyphenols are quite well absorbed and a significant 
proportion is excreted in the urine; examples include gallic acid, the isoflavones 
genistein and daidzein, and the (citrus) flavanones hesperetin and naringenin 
(Manach et al., 2005). However, for others such as anthocyanins, much less than 1% 
of the oral dose is recovered in urine and plasma concentrations peak in the low 
nanomolar range (Manach et al., 2005). To date, the highest concentrations of 
polyphenols observed in plasma following oral ingestion by humans have been 
around 1-10 µM. These concentrations are only observed for relatively large doses of 
polyphenols from supplements or polyphenol-rich foods and beverages that contain 
the more bioavailable flavonoids, such as monomeric flavan-3-ols, isoflavones and 
flavanones. 
 
Metabolism during the first pass 
Flavonoids and other polyphenols are extensively metabolised during absorption 
from the gut, and the typical products are phase-2 conjugates (i.e. glucuronidated, 
sulfated and methylated derivatives of the parent polyphenol (Kroon et al., 2004)). 
Indeed, for many polyphenols, the conjugation process is so efficient that the 
aglycone is not detectable in plasma and urine (Donovan et al., 2006). The first pass 
includes the small intestine and the liver, and both are capable of metabolising 
polyphenols (Manach et al., 2004). The kidney also has significant capacity to modify 
polyphenols but there is little evidence to support a major role for this organ, probably 
because it is precluded from contributing by the efficiency of the small intestine and 
liver in these activities. The major plasma and urinary forms resulting from ingestion 
of different polyphenols have been summarised by Kroon et al. (2004). Many red 
wine polyphenols (flavonols, catechin / epicatechin, resveratrol, phenolic acids) are 
efficiently conjugated and are present in plasma predominantly as phase-2 
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conjugated metabolites. For example, following oral ingestion, 100% of quercetin and 
virtually all resveratrol is present as glucuronidated and sulfated conjugates of the 
aglycone or a methylated derivative (Day et al., 2001; Vitaglione et al., 2005) (see 
Figure 2).  
 
The flavanol monomers, (+)-catechin and (-)-epicatechin, are also conjugated during 
absorption. The major products are glucuronidated and sulfated conjugates of the 
parent aglycone or methylated derivatives (Kroon et al., 2004). However, 
anthocyanins (the brightly coloured components responsible for the red colour of 
wine) are often not conjugated during absorption, and in this respect, they are rather 
unique. Although the mechanisms of absorption for anthocyanins are not well 
understood, the fact that they appear in plasma un-metabolised and at extremely low 
concentrations, and that the urinary yield typically is extremely low (Manach et al., 
2005), may indicate that these compounds escape intestinal metabolism by passing 
between the enterocytes rather than through them.  
 
What are effects of metabolism on biological activity? 
Due to the lack of commercially-available standards, and the technical difficulties 
associated with their synthesis, there are only a limited number of reports concerned 
with the biological activities of authentic polyphenol phase-2 conjugates. Readers are 
referred to Kroon et al. (2004) and Williamson et al. (2005) that discuss much of the 
available data. Many of the studies concerned with the effects of conjugation on 
biological activity have focussed on quercetin, the conjugates of which have been 
synthesised chemically (Needs & Kroon, 2006). For example, conjugation has been 
shown to detrimentally affect the ability of quercetin to inhibit xanthine oxidase and 
lipoxygenase enzyme activities in vitro, although the loss of potency was heavily 
dependent on the position of conjugation; the 3‟- and 4‟-glucuronides were only 
slightly less effective inhibitors of xanthine oxidase (Day et al., 2000). Quercetin 
glucuronides have also been shown to inhibit the N-acetylation of the arylamine 
carcinogen 2-aminofluorene by human acute myeloid leukaemia (HL-60) cells (Kuo et 
al., 2002), inhibit lung cancer cell growth via cell cycle arrest and induction of 
apoptosis (Yang et al., 2006), prevent angiotensin-II-induced vascular cell 
hypertrophy in cultured rat aortic smooth muscle cells via inhibition of JNK and AP-1 
signalling pathways (Yoshizumi et al., 2002) and down-regulate transcription of 
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human cyclooxygenase-2 (COX-2) (O‟Leary et al., 2004; de Pascual-Teresa et al., 
2004). In contrast, Donnini et al. (2006) provide evidence that whereas quercetin and 
quercetin-3-glucuronide inhibited vascular endothelial growth factor (VEGF)-induced 
changes in cell functions and angiogenesis, quercetin-3‟-sulfate promoted cell 
proliferation and angiogenesis. Therefore, phase-2 conjugation is an important factor 
to consider when assessing the potential biological activities of polyphenols, as the 
effects can be both profound and unpredictable. To date, there are no reports 
documenting the relative biological activity of resveratrol phase-2 conjugates, even 
though these represent the predominant forms in vivo following resveratrol ingestion.  
 
In summary, further research is required to understand the role of resveratrol and 
other polyphenols in providing the additional benefits of consumption of low to 
moderate amounts of red wine, compared to white wine, beer or spirits. However, the 
various risks associated with drinking alcoholic beverages has so far prevented a 
fully controlled clinical trial to determine the effects of moderate red wine 
consumption on disease risk. 
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FIGURE LEGENDS 
 
Figure 1: Chemical structures of resveratrol, epicatechin, gallic acid and 
quercetin. 
 
 
Figure 2. Intestinal metabolism and transport of resveratrol. 
Resveratrol aglycone is taken up by the enterocytes, probably by passive diffusion, 
and is efficiently conjugated with glucuronic acid and sulfate through the action of 
UDP-glucuronosyl transferase and aryl-sulfatase enzymes. Methylation has not been 
observed, presumably due to the lack of a catechol function in the resveratrol 
molecule, which is a requirement for catechol-O-methyltransferase (COMT). The 
conjugates are transported out of the enterocytes by as yet unconfirmed processes, 
but it is thought that efflux transporters of the multi-drug resistance proteins (MRP) 
family are involved (several are indicated). Resveratrol sulfate is preferentially 
transported to the apical (luminal) side of polarised enterocytes, while resveratrol 
glucuronides are preferentially effluxed to the basolateral (serosal) side (Kaldas et al., 
2003). Hence, the predominant form of resveratrol in human blood following oral 
dosing is resveratrol glucuronide (95-99% of total plasma resveratrol). 
Solid arrows, probable active transport process; Dashed arrows, diffusion; Res, 
resverastrol; GlcA, glucuronic acid; SO4-, sulphate; MRP, multi-drug-resistance 
protein; BCRP, breast cancer resistance protein; PgP, P-glycoprotein. 
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